CASIN
Based on 10 publication(s) in Google Scholar
CASIN is a selective GTPase Cdc42 inhibitor with an IC50 of 2 uM. CASIN can be used for the research of cancer.
For research use only. We do not sell to patients.
- Purity: 99.89%
- CAS No.: 425399-05-9
- Formula: C20H22N2O
- Molecular Weight:306.40
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) CASIN
More- Nat Commun. 2022 Nov 11;13(1):6840. [Abstract]
- Clin Transl Med. 2022 Jun;12(6):e850. [Abstract]
- Ecotoxicol Environ Saf. 2022 Feb:231:113208. [Abstract]
- Toxicol Sci. 2018 Sep 1;165(1):254-266. [Abstract]
- J Mol Med (Berl). 2023 Dec;101(12):1567-1585. [Abstract]
- iScience. 2025 Jul 14;28(7):112971. [Abstract]
- BMC Cancer. 2025 May 28;25(1):956. [Abstract]
- Clin Immunol. 2023 Nov:256:109777. [Abstract]
- Birth Defects Res. 2021 Mar 15;113(5):427-438. [Abstract]
- Res Sq. 2026 Apr 26.
-
In Vivo Imaging
-
Histological Imaging/Staining
-
ELISA
Biological Activity
IC50: 2 μM (GTPase Cdc42)[1]
CASIN (0-10 μM; 3 d) inhibits the growth of AMO-1, ARH-77, IM-9 , JJN-3, L-363, MOLP-8 and RPMI-8226/S cells[1]. CASIN (0-10 μM; 16 h) inhibits melphalan induced FANCD2 mono-ubiquitination in LR5 cells but shows no effect to S cells[1]. CASIN (5 μM; 2 d) increases cell apoptosis of bortezomib-resistant MM patient cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:AMO-1, ARH-77, IM-9 , JJN-3, L-363, MOLP-8 and RPMI-8226/S cells
-
Concentration:0-10 μM
-
Incubation Time:3 days
-
Result:Inhibited MM cell lines including AMO-1, ARH-77, IM-9 , JJN-3, L-363, MOLP-8 and RPMI-8226/S cells with GI50s vof 3.23, 4.31, 4.87, 2.56, 4.64, 4.67 and 3.97 μM, respectively.
-
Cell Line:MM (S) and melphalan-resistant (LR5) MM cells
-
Concentration:5 μM
-
Incubation Time:16 hours
-
Result:Abolished melphalan induced FANCD2 mono-ubiquitination and DNA damage in LR5, sensitized LR5 to melphalan-induced cell death by blocking FANCD2-mediated DNA damage repair.
-
Cell Line:Bortezomib-resistant MM patients cells
-
Concentration:5 μM
-
Incubation Time:2 days
-
Result:2-fold increased cell apoptosis in the cell derived from bortezomib-resistant MM patients.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NSG mice with busulfan injection[3]
-
Dosage:20 mg/kg
-
Administration:Intraperitoneal injection; 20 mg/kg 2 times a day
-
Result:Significantly prolonged the lifespan of xenografts mice better than bortezomib, and showed a leading position when combined with bortezomib.
Chemical Information
-
CAS No. 425399-05-9
-
Appearance Solid
-
Molecular Weight 306.40
-
Formula C20H22N2O
-
Color Yellow to brown
-
SMILES
OCCNC1C(NC2=C3C=C(C4=CC=CC=C4)C=C2)=C3CCC1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
pTINCR microprotein promotes epithelial differentiation and suppresses tumor growth through CDC42 SUMOylation and activation. [Abstract]2022 Nov 11;13(1):6840. PMID: 36369429 -
Clin Transl Med
Uterus globulin associated protein 1 (UGRP1) binds podoplanin (PDPN) to promote a novel inflammation pathway during Streptococcus pneumoniae infection. [Abstract]2022 Jun;12(6):e850. PMID: 35652821
CASIN purchased from MedChemExpress. Usage Cited in: Clin Transl Med. 2022 Jun;12(6):e850. [Abstract]
PEMs were treated with RhoA inhibitor (CCG‐1423, 20 μM), Cdc42 inhibitor (CASIN, 20 μM), Rac1 inhibitor (1A‐116, 10 μM) or dual Cdc42/Rac1 inhibitor (MBQ‐167, 10 μM) for 1 h followed by Pam3CSK4 (0.5 μg/ml) and BSA or UGRP1 (0.5 μg/ml) treatment for 9 h to measure IL‐6 expression by ELISA.
-
Ecotoxicol Environ Saf
Cadmium exposure reprograms energy metabolism of hematopoietic stem cells to promote myelopoiesis at the expense of lymphopoiesis in mice. [Abstract]2022 Feb:231:113208. PMID: 35051759 -
Toxicol Sci
Cadmium Activates Noncanonical Wnt Signaling to Impair Hematopoietic Stem Cell Function in Mice. [Abstract]2018 Sep 1;165(1):254-266. PMID: 29939372 -
J Mol Med (Berl)
Vav2 promotes ductus arteriosus anatomic closure via the remodeling of smooth muscle cells by Rac1 activation. [Abstract]2023 Dec;101(12):1567-1585. PMID: 37804474 -
iScience
CDC42-effector interaction inhibitors alter patterns of vessel arborization in skin and tumors in vivo. [Abstract]2025 Jul 14;28(7):112971. PMID: 40950721
CASIN purchased from MedChemExpress. Usage Cited in: iScience. 2025 Jul 14;28(7):112971. [Abstract]
Representative stack images of skin vessels from wild-type mice treated with vehicle or 40 mg/kg CASIN intraperitoneally. Bottom of each stack includes the 2D AngioTool tracing of pixels in grayscale.
CASIN purchased from MedChemExpress. Usage Cited in: iScience. 2025 Jul 14;28(7):112971. [Abstract]
Representative H&E staining of C57B6 skin obtained from CASIN or vehicle-treated mice is shown. The thickness of the dermis was quantified and compared between vehicle and drug-treated mice.
-
BMC Cancer
TRPM2 channels mediate ROS-induced actin remodeling and cell migration of prostate cancer cells. [Abstract]2025 May 28;25(1):956. PMID: 40437388 -
Clin Immunol
C-terminal variants in CDC42 drive type I interferon-dependent autoinflammation in NOCARH syndrome reversible by ruxolitinib. [Abstract]2023 Nov:256:109777. PMID: 37741518 -
Birth Defects Res
Lithium-induced overexpression of β-catenin delays murine palatal shelf elevation by Cdc-42 mediated F-actin remodeling in mesenchymal cells. [Abstract]2021 Mar 15;113(5):427-438. PMID: 33300673 -
Solvent & Solubility
DMSO : ≥ 31 mg/mL (101.17 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.79 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.79 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Florian MC et al. Cdc42 activity regulates hematopoietic stem cell aging and rejuvenation. Cell Stem Cell, 2012 May 4, 10(5):520-30. [Content Brief]
[2]. Nguyen P, et al. Rational Targeting of Cdc42 Overcomes Drug Resistance of Multiple Myeloma. Front Oncol. 2019 Oct 1;9:958. doi: 10.3389/fonc.2019.00958. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2637 mL | 16.3185 mL | 32.6371 mL | 81.5927 mL |
| 5 mM | 0.6527 mL | 3.2637 mL | 6.5274 mL | 16.3185 mL | |
| 10 mM | 0.3264 mL | 1.6319 mL | 3.2637 mL | 8.1593 mL | |
| 15 mM | 0.2176 mL | 1.0879 mL | 2.1758 mL | 5.4395 mL | |
| 20 mM | 0.1632 mL | 0.8159 mL | 1.6319 mL | 4.0796 mL | |
| 25 mM | 0.1305 mL | 0.6527 mL | 1.3055 mL | 3.2637 mL | |
| 30 mM | 0.1088 mL | 0.5440 mL | 1.0879 mL | 2.7198 mL | |
| 40 mM | 0.0816 mL | 0.4080 mL | 0.8159 mL | 2.0398 mL | |
| 50 mM | 0.0653 mL | 0.3264 mL | 0.6527 mL | 1.6319 mL | |
| 60 mM | 0.0544 mL | 0.2720 mL | 0.5440 mL | 1.3599 mL | |
| 80 mM | 0.0408 mL | 0.2040 mL | 0.4080 mL | 1.0199 mL | |
| 100 mM | 0.0326 mL | 0.1632 mL | 0.3264 mL | 0.8159 mL |